Nanomedicine, Volume IIA: Biocompatibility

© 2003 Robert A. Freitas Jr. All Rights Reserved.

Robert A. Freitas Jr., Nanomedicine, Volume IIA: Biocompatibility, Landes Bioscience, Georgetown, TX, 2003


References 2300-2399

2300. “Herbal Snuffs, A Seventeenth Century Fancy”;

2301. O.Y. Chan, C.S. Lee, K.T. Tan, T. Thirumoorthy, “Health problems among spice grinders,” J. Soc. Occup. Med. 40(Autumn 1990):111-115.

2302. C. Theander, M. Bende, “Nasal hyperreactivity to newspapers,” Clin. Exp. Allergy 19(January 1989):57-58.

2303. S. Kira, Y. Nogami, K. Taketa, M. Ogata, “Size-selective sampling of oil mist in air and subjective symptoms among machine workers,” Ind. Health 35(July 1997):394-398.

2304. B.W. Whitman, R.J. Packer, “The photic sneeze reflex: literature review and discussion,” Neurology 43(May 1993):868-871.

2305. R.A. Breitenbach, P.K. Swisher, M.K. Kim, B.S. Patel, “The photic sneeze reflex as a risk factor to combat pilots,” Mil. Med. 158(December 1993):806-809.

2306. F. Wallois, L. Bodineau, J.M. Macron, D. Marlot, B. Duron, “Role of respiratory and non-respiratory neurones in the region of the NTS in the elaboration of the sneeze reflex in cat,” Brain Res. 768(12 September 1997):71-85.

2307. S.I. Sekizawa, T. Ishikawa, G. Sant’Ambrogio, “Asymmetry in reflex responses of nasal muscles in anesthetized guinea pigs, J. Appl. Physiol. 85(July 1998):123-128.

2308. F. Wallois, F. Gros, K. Masmoudi, N. Larnicol, “C-Fos-like immunoreactivity in the cat brainsteam evoked by sneeze-inducing air puff stimulation of the nasal mucosa,” Brain Res. 687(31 July 1995):143-154.

2309. D.C. Abramson, “Sudden unexpected sneezing during the insertion of peribulbar block under propofol sedation,” Can. J. Anaesth. 42(August 1995):740-743.

2310. C. Secher, J. Kirkegaard, P. Borum, A. Maansson, P. Osterhammel, N. Mygind, “Significance of H1 and H2 receptors in the human nose: rationale for topical use of combined antihistamine preparations,” J. Allergy Clin. Immunol. 70(September 1982):211-218.

2311. J.N. Baraniuk, M. Kaliner, “Neuropeptides and nasal secretion,” Am. J. Physiol. 261(October 1991):L223-L235.

2312. J.S. Lacroix, “Environment and nasal hyperreactivity,” Rev. Med. Suisse Romande 119(August 1999):619-621. In French.

2313. K.E. Thomas, S. Ollier, H. Ferguson, R.J. Davies, “The effect of intranasal azelastine, Rhinolast, on nasal airways obstruction and sneezing following provocation testing with histamine and allergen,” Clin. Exp. Allergy 22(June 1992):642-647.

2314. K. Javorka, Z. Tomori, L. Zavarska, “Protective and defensive airway reflexes in premature infants,” Physiol. Bohemoslav. 29(1980):29-35.

2315. J.M. Gwaltney Jr., J.O. Hendley, C.D. Phillips, C.R. Bass, N. Mygind, B. Winther, “Nose blowing propels nasal fluid into the paranasal sinuses,” Clin. Infect. Dis. 30(February 2000):387-391.

2316. K. Javorka, Z. Tomori, L. Zavarska, “Mechanics of breathing during sneezing and crying in premature newborns,” Eur. J. Respir. Dis. 63(September 1982):442-448.

2317. S. Nonaka, T. Unno, Y. Ohta, S. Mori, “Sneeze-evoking region within the brainstem,” Brain Res. 511(19 March 1990):265-270.

2318. Louis M. Aledort, Leon W. Hoyer, Jeanne M. Lusher, Howard M. Reisner, Gilbert C. White II, eds., Inhibitors to Coagulation Factors, Plenum Press, New York, 1995.

2319. Arthur A. Sasahara, Joseph Loscalzo, eds., New Therapeutic Agents in Thrombosis and Thrombolysis, Marcel Dekker, New York, 1997.

2320. Alvin H. Schmaier, “Chapter 5. Contact Activation,” in Joseph Loscalzo, Andrew I. Schafer, eds., Thrombosis and Hemorrhage, Second Edition, Williams & Wilkins, Baltimore, MD, 1998, pp. 105-127.

2321. Alvin H. Schmaier, “Chapter 4. Gene Expression, Regulation and Cell Surface Presentation of the Kininogens,” in Stephen G. Farmer, ed., The Kinin System, Handbook of Immunopharmacology Systems, Academic Press, New York, 1997, pp. 57-70.

2322. Robert Terkeltaub, “Chapter 49. Gout: Crystal-Induced Inflammation,” in John I. Gallin, Ira M. Goldstein, Ralph Snyderman, eds., Inflammation: Basic Principles and Clinical Correlates, Second Edition, Raven Press, New York, 1992, pp. 977-981.

2323. I.Y. Adamson, D.H. Bowden, “Role of polymorphonuclear leukocytes in silica-induced pulmonary fibrosis,” Am. J. Pathol. 117(October1984):37-43.

2324. A.J. Reginato, B. Kurnik, “Calcium oxalate and other crystals associated with kidney diseases and arthritis,” Semin. Arthritis Rheum. 18(February 1989):198-224.

2325. L.M. Ryan, D.J. McCarty, “Calcium pyrophosphate crystal deposition disease,” in D.J. McCarty, ed., Arthritis and Allied Conditions, Lea & Febiger, Philadelphia, PA, 1989, pp. 1711-1736.

2326. P.B. Halverson, D.J. McCarty, “Basic calcium phosphate (apatite, octacalcium phosphate, tricalcium phosphate) crystal deposition diseases,” in D.J. McCarty, ed., Arthritis and Allied Conditions, Lea & Febiger, Philadelphia, PA, 1989, pp. 1737-1755.

2327. R, Terkeltaub, M. Ginsberg, D.J. McCarty, “Pathogenesis and treatment of crystal-induced inflammation,” in D.J. McCarty, ed., Arthritis and Allied Conditions, Lea & Febiger, Philadelphia, PA, 1989, pp. 1691-1710.

2328. P.C. Giclas, M.H. Ginsberg, N.R. Cooper, “Immunoglobulin G independent activation of the classical complement pathway by monosodium urate crystals,” J. Clin. Invest. 63(April 1979):759-765.

2329. M.H. Ginsberg, B. Jaques, C.G. Cochrane, J.H. Griffin, “Urate crystal-dependent cleavage of Hageman factor in human plasma and synovial fluid,” J. Lab. Clin. Med. 95(April 1980):497-506.

2330. N.S. Mandel, “The structural basis of crystal-induced membranolysis,” Arthritis Rheum. 19(May-June 1976):439-445 (Suppl).

2331. Henry O. Trowbridge, Robert C. Emiling, Inflammation: A Review of the Process, Fifth Edition, Quintessence Publishing Co., Inc., Chicago, IL, 1997.

2332. M. Sela, “Chapter 1. Overview: Antigens,” in D.M. Weir, L.A. Herzenberg, Caroline Blackwell, Leonore A. Herzenberg, eds., Volume I: Immunochemistry, Fourth Edition, Blackwell Scientific Publications, Oxford, U.K., 1986, pp. 1.1-1.7.

2333. B. Casu, G. Grazioli, N. Razi, et al, “Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5,” Carbohydr. Res. 263(1994):271-284.

2334. R.F. Noel Jr., T.T. Sato, C. Mendez, et al, “Activation of human endothelial cells by viable or heat-killed gram-negative bacteria requires soluble CD14,” Infect. Immun. 63(1995):4046-4053.

2335. H.M. Schrager, J.G. Rheinwald, M.R. Wessels, “Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection,” J. Clin. Invest. 98(1 November 1996):1954-1958.

2336. J.W. Ezzell, S.L. Welkos, “The capsule of bacillus anthracis, a review,” J. Appl. Microbiol. 87(August 1999):250.

2337. M. Sela, E. Zisman, “Different roles of D-amino acids in immune phenomena,” FASEB J. 11(May 1997):449-456.

2338. M.H. Van Regenmortel, S. Muller, “D-peptides as immunogens and diagnostic reagents,” Curr. Opin. Biotechnol. 9(August 1998):377-382.

2339. N. Benkirane, M. Friede, G. Guichard, J.P. Briand, M.H. Van Regenmortel, S. Muller, “Antigenicity and immunogenicity of modified synthetic peptides containing D-amino acid residues. Antibodies to a D-enantiomer do recognize the parent L-hexapeptide and reciprocally,” J. Biol. Chem. 268(15 December 1993):26279-26285.

2340. H. Bruckner, D. Becker, M. Lupke, “Chirality of amino acids of microorganisms used in food biotechnology,” Chirality 5(1993):385-392.

2341. Y.C. Lee, C.A. Hoppe, K. Kawaguchi, P. Lin, “Nondegradable carbohydrate ligands,” Methods Enzymol. 138(1987):404-409.

2342. D.A. Bautista, R.B. Pegg, P.J. Shand, “Effect of L-glucose and D-tagatose on bacterial growth in media and a cooked cured ham product,” J. Food Prot. 63(January 2000):71-77.

2343. A. Bar, W.R. Leeman, “L-Sorbose but not D-tagatose induces hemolysis of dog erythrocytes in vitro,” Regul. Toxicol. Pharmacol. 29(April 1999):S43-S45.

2344. J. Lubinski, L. Wang, D. Mastellos, A. Sahu, J.D. Lambris, H.M. Friedman, “In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC,” J. Exp. Med. 190(6 December 1999):1637-1646; I. Kostavasili, A. Sahu, H.M. Friedman, R.J. Eisenberg, G.H. Cohen, J.D. Lambris, “Mechanism of complement inactivation by glycoprotein C of herpes simplex virus,” J. Immunol. 158(15 February 1997):1763-1771; H.M. Friedman, L. Wang, N.O. Fishman, J.D. Lambris, R.J. Eisenberg, G.H. Cohen, J. Lubinski, “Immune evasion properties of herpes simplex virus type 1 glycoprotein gC,” J. Virol. 70(July 1996):4253-4260.

2345. H.P. Huemer, C. Larcher, N.E. Coe, “Pseudorabies virus glycoprotein III derived from virions and infected cells binds to the third component of complement,” Virus Res. 23(May 1992):271-280.

2346. A. Neil Barclay, Marion H. Brown, S.K. Alex Law, Andrew J. McKnight, Michael G. Tomlinson, P. Anton van der Merwe, The Leucocyte Antigen FactsBook, Second Edition, Academic Press, New York, 1997.

2347. A. Alcami, G.L. Smith, “A mechanism for the inhibition of fever by a virus,” Proc. Natl. Acad. Sci. (USA) 93(1 October 1996):11029-11034.

2348. G.L. Smith, J.A. Symons, A. Khanna, A. Vanderplasschen, A. Alcami, “Vaccinia virus immune evasion,” Immunol. Rev. 159(October 1997):137-154.

2349. Jose Aramburu, Michael B. Yaffe, Cristina Lopez-Rodriguez, Lewis C. Cantley, Patrick G. Hogan, Anjana Rao, “Affinity-Driven Peptide Selection of an NFAT Inhibitor More Selective Than Cyclosporin A,” Science 285(24 September 1999):2129-2133.

2350. H.T. Lau, M. Yu, A. Fontana, C.J. Stoeckert Jr., “Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice,” Science 273(5 July 1996):109-112.

2351. S.E. Turvey, V. Gonzalez-Nicolini, C.I. Kingsley, A.T. Larregina, P.J. Morris, M.G. Castro, P.R. Lowenstein, K.J. Wood, “Fas ligand-transfected myoblasts and islet cell transplantation,” Transplantation 69(15 May 2000):1972-1976.

2352. Craig A. Smith, T. Davis, D. Anderson, L. Solam, M.P. Beckmann, R. Jerzy, S.K. Dower, D. Cosman, R.G. Goodwin, “A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins,” Science 248(25 May 1990):1019-1023.

2353. Chris Upton, Karen Mossman, Grant McFadden, “Encoding of a Homolog of the IFN-Gamma Receptor by Myxoma Virus,” Science 258(20 November 1992):1369-1372.

2354. A. Alcami, G.L. Smith, “Soluble interferon-gamma receptors encoded by poxviruses,” Comp. Immunol. Microbiol. Infect. Dis. 19(September 1996):305-317; “Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity,” J. Virol. 69(August 1995):4633-4639.

2355. C.A. Smith, F.Q. Hu, T.D. Smith, C.L. Richards, P. Smolak, R.G. Goodwin, D.J. Pickup, “Compox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT alpha,” Virology 223(1 September 1996):132-147.

2356. S. Zhang, L. Yan, M. Altman, M. Lassle, H. Nugent, F. Frankel, D.A. Lauffenburger, G.M. Whitesides, A. Rich, “Biological surface engineering: a simple system for cell pattern formation,” Biomaterials 20(July 1999):1213-1220.

2357. V.M. Braud, D.S. Allan, C.A. O’Callaghan, K. Soderstrom, A. D’Andrea, G.S. Ogg, S. Lazetic, N.T. Young, J.I. Bell, J.H. Phillips, L.L. Lanier, A.J. McMichael, “HLA-E binds to natural killer cell receptors CD94/NKG2A, B, and C,” Nature 391(19 February 1998):795-799; 740-741 and 743 (comment).

2358. N. Lee, M. Llano, M. Carretero, A. Ishitani, F. Navarro, M. Lopez-Botet, D.E. Geraghty, “HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A,” Proc. Natl. Acad. Sci. (USA) 95(28 April 1998):5199-5204, 4791-4794 (comment);

2359. C.A. O’Callaghan, “Molecular basis of human natural killer cell recognition of HLA-E (human leucocyte antigen-E) and its relevance to clearance of pathogen-infected and tumour cells,” Clin. Sci. (Colch) 99(1 July 2000):9-17; C.A. O’Callaghan, “Natural killer cell surveillance of intracellular antigen processing pathways mediated by recognition of HLA-E and Qa-1b by CD94/NKG2 receptors,” Microbes Infect. 2(April 2000):371-380.

2360. B. Jansen, M. Rinck, P. Wolbring, A. Strohmeier, T. Jahns, “In vitro evaluation of the antimicrobial efficacy and biocompatibility of a silver-coated central venous catheter,” J. Biomater. Appl. 9(July 1994):55-70; A. Oloffs, C. Grosse-Siestrup, S. Bisson, M. Rinck, R. Rudolph, U. Gross, “Biocompatibility of silver-coated polyurethane catheters and silver-coated Dacron material,” Biomaterials 15(August 1994):753-758.

2361. L.C. Fung, A.E. Khoury, S.I. Vas, C. Smith, D.G. Oreopoulos, M.W. Mittelman, “Biocompatibility of silver-coated peritoneal dialysis catheter in a porcine model,” Perit. Dial. Int. 16(July-August 1996):398-405.

2362. K.S. Tweden, J.D. Cameron, A.J. Razzouk, W.R. Holmberg, S.J. Kelly, “Biocompatibility of silver-modified polyester for antimicrobial protection of prosthetic valves,” J. Heart Valve Dis. 6(September 1997):553-561.

2363. M. Boswald, K. Mende, W. Bernschneider, S. Bonakdar, H. Ruder, H. Kissler, E. Sieber, J.P. Guggenbichler, “Biocompatibility testing of a new silver-impregnated catheter in vivo,” Infection 27(1999):S38-S42 (Suppl 1).

2364. J. McLean, “The thromboplastic action of cephalin,” Am. J. Physiol. 41(1916):250-257.

2365. M. PetitouJ.P. Herault, A. Bernat, P.A. Driguez, P. Duchaussoy, J.C. Lormeau, J.M. Herbert, “Synthesis of thrombin-inhibiting heparin mimetics without side effects,” Nature 398(1 April 1999):417-422.

2366. F. Fabris, G. Luzzatto, P.M. Stefani, B. Girolami, G. Cella, A. Girolami, “Heparin-induced thrombocytopenia,” Haematologica 85(January 2000):72-81.

2367. P.M. Newman, B.H. Chong, “Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation,” Blood 96(1 July 2000):182-187.

2368. W. Emlen, M. Mannik, “Kinetics and mechanisms for removal of circulating single-stranded DNA in mice,” J. Exp. Med. 147(1 March 1978):684-699.

2369. W. Emlen, M. Mannik, “Effect of preformed immune complexes on the clearance and tissue localization of single-stranded DNA in mice,” Clin. Exp. Immunol. 40(May 1980):264-272.

2370. Y.M. Lo, et al, “Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis,” Am. J. Hum. Genet. 62(April 1998):768-775.

2371. Y.M. Lo, “Fetal DNA in maternal plasma,” Ann. N.Y. Acad. Sci. 906(April 2000):141-147.

2372. Y.M. Lo, T.N. Leung, M.S. Tein, I.L. Sargent, J. Zhang, T.K. Lau, C.J. Haines, C.W. Redman, “Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia,” Clin. Chem. 45(February 1999):184-188.

2373. Y.M. Lo, J. Zhang, T.N. Leung, T.K. Lau, A.M. Chang, N.M. Hjelm, “Rapid clearance of fetal DNA from maternal plasma,” Am. J. Hum. Genet. 64(January 1999):218-224.

2374. A. Loviselli, F. Velluzzi, R. Pala, A. Marcello, P. Nurchis, A. Mathieu, L. Bartalena, E. Martino, L. Grasso, “Circulating antibodies to DNA-related antigens in patients with autoimmune thyroid disorders,” Autoimmunity 14(1992):33-36.

2375. P. Riboldi, R. Asero, L. Marazzini, E. Longhini, P. Cherubini, M. Pacetti, F. Invernizzi, “Detection of circulating DNA in plasma of patients with pulmonary embolism by counterimmunoelectrophoresis,” Respiration 45(1984):45-49.

2376. C.R. Steinman, “Circulating DNA in polyarteritis nodosa and related syndromes,” Arthritis Rheum. 25(December 1982):1425-1430.

2377. B. Shapiro, M. Chakrabarty, E.M. Cohn, S.A. Leon, “Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease,” Cancer 51(1 June 1983):2116-2120.

2378. C.R. Steinman, A. Ackad, “Appearance of circulating DNA during hemodialysis,” Am. J. Med. 62(May 1977):693-697.

2379. F.G. Cosio, L.A. Hebert, D.J. Birmingham, B.L. Dorval, A.P. Bakaletz, G.A. Kujala, J.C. Edberg, R.P. Taylor, “Clearance of human antibody/DNA immune complexes and free DNA from the circulation of the nonhuman primate,” Clin. Immunol. Immunopathol. 42(January 1987):1-9.

2380. W. Emlen, M. Mannik, “Clearance of circulating DNA-anti-DNA immune complexes in mice,” J. Exp. Med. 155(1 April 1982):1210-1215.

2381. W. Emlen, M. Mannik, “Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA,” Clin. Exp. Immunol. 56(April 1984):185-192.

2382. S. Bosi, T. Da Ros, S. Castellano, E. Banfi, M. Prato, “Antimycobacterial activity of ionic fullerene derivatives,” Bioorg. Med. Chem. Lett. 10(15 May 2000):1043-1045.

2383. J.P. Chiron, J. Lamande, F. Moussa, F. Trivin, R. Ceolin, “Effect of `micronized’ C60 fullerene on the microbial growth in vitro,” Ann. Pharm. Fr. 58(May 2000):170-175. In French.

2384. L.K. Panina, V.E. Kurochkin, E.V. Bogomolvova, A.A. Evstrapov, N.G. Spitsing, Dokl. RAS 351(1997):275.

2385. “Carbon nanotube antibody,” Carbon Nanotube Research Group, Center for Advanced Materials and nanotechnology, New York University;

2386. William A. Goddard, III, Nagarajan Vaidehi, Wely Floriano, Brian Palmer, Changmoon Park, Deepshika Datta, “ Bionanotechnology – de novo simulations and design,” lecture at the 8th Foresight Conference on Molecular Nanotechnology, November 2000;

2387. B.C. Braden, F.A. Goldbaum, B.X. Chen. A.N. Kirschner, S.R. Wilson, B.F. Erlanger, “X-ray crystal structure of an anti-buckminsterfullerene antibody fab fragment: biomolecular recognition of C60,” Proc. Natl. Acad. Sci. (USA) 97(24 October 2000):12193-12197;

2388. “Anti C60 Fullerene antibody,” Bioactive Fullerenes Research Group, Center for Advanced Materials and nanotechnology, New York University;

2389. B.C. Braden, B.F. Erlanger, B.-X. Kirschner, S.R. Wilson, “Monoclonal antibodies to fullerenes,” in N. Martin, M. Maggini, D.M. Guldi, eds., Fullerenes 2000, Volume 9: Functionalized Fullerenes, The Electrochemical Society, Spring 2000, pp. 233-239.

2390. S.R. Wilson, “Biological Aspects of Fullerenes,” in K.M. Kadish, R.S. Ruoff, eds., Fullerenes: Chemistry, Physics, and Technology, John Wiley and Sons, New York, 2000, pp. 437-465.

2391. S. Brown, M. Sarikaya, E. Johnson, “A genetic analysis of crystal growth,” J. Mol. Biol. 299(9 June 2000):725-735; S. Brown, “Metal-recognition by repeating polypeptides,” Nat. Biotechnol. 15(March 1997):269-272. See also: Rosemary Braun, Klaus Schulten, Dan Heidel, Mehmet Sarikaya, “Molecular Dynamics Study of Inorganic Surface Recognition by Engineered Proteins,” 8th Foresight Conference on Molecular Nanotechnology, November 2000;

2392. “Black Diamond – Diamond Grit,” Material Safety Data Sheet, NSN: 513000F029900, 23 September 1993;

2393. “Kay Industrial Diamond – Premium SJK-5 Synthetic Diamond Powder,” Material Safety Data Sheet, NSN: 535000N029770, 12 September 1995;

2394. “The Amplex – Diamond Powder,” Material Safety Data Sheet, NSN: 535000N056606, 4 January 1995;

2395. J.C. Roberts, M.K. Bhalgat, R.T. Zera, “Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers,” J. Biomed. Mater. Res. 30(January 1996):53-65.

2396. H. Yoo, P. Sazani, R.L. Juliano, “PANAM dendrimers as delivery agents for antisense oligonucleotides,” Pharm. Res. 16(December 1999):1799-1804.

2397. N. Malik, R. Wiwattanapatapee, R. Klopsch, K. Lorenz, H. Frey, J.W. Weener, E.W. Meijer, W. Paulus, R. Duncan, “Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo,” J. Control Release 65(1 March 2000):133-148; 68(10 August 2000):299-302 (erratum).

2398. C. Kojima, K. Kono, K. Maruyama, T. Takagishi, “Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs,” Bioconjug. Chem. 11(20 November 2000):910-917.

2399. Lajos Balogh, Douglas R. Swanson, Donald A. Tomalia, Gary L. Hagnauer, Albert T. McManus, “Dendrimer-silver complexes and nanocomposites as antimicrobial agents,” Nano Letters 1(2001):18-21;


Last updated on 16 April 2004